Clinical trials: Indigestion
Dyspepsia
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
- Trial name
- NCT00232024
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 1,296 people
- Sponsor
- Novartis
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Heartburn, Indigestion
A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants
Researchers are looking for a better way to treat people who have heartburn, indigestion, and problems due to excessive stomach acid. These are common problems which can affect daily life and disturb sleep during the night-time.
- Conditions
- Heartburn, Indigestion, Stomach Acid Related Symptoms, Nocturnal Stomach Acid Related Symptoms
- Trial name
- NCT06293326
- Testing
- bi-layer calcium carbonate tablet (BAY1180654), Immediate release calcium carbonate tablet (BAY1180654)
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Bayer
Helicobacter Pylori Infection
Efficacy and Safety of Lacidofil® STRONG as an Adjuvant for Helicobacter Pylori Treatment in Non-ulcer Dyspepsia
Treatment for H. pylori eradication includes antibiotics. The treatment has decreased its efficiency (lower capability to eradicate the infection) due to increasing antibiotic resistance in the population.
- Trial name
- NCT04473079
- Testing
- Lacidofil
- Where
- Thailand
- Volunteers
- 90 people
- Sponsor
- Lallemand Health Solutions
Dyspepsia, Heartburn
Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn.
Evaluation of the clinical efficacy of two medical devices, Mipolixin® and Poliprotect®, in improving the overall symptom severity of functional dyspesia and/or heartburn
- Trial name
- NCT03531372
- Testing
- Mipolixin®, Poliprotect®
- Where
- 11 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Aboca Spa Societa' Agricola
Indigestion, Nausea
YM443 in Subjects With Functional Dyspepsia
The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
- Trial name
- NCT00102310
- Testing
- YM443
- Where
- 59 sites in United States
- Volunteers
- 416 people
- Sponsor
- Astellas Pharma Inc
Dyspepsia
Study of Motilitone to Treat Functional Dyspepsia
This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.
- Trial name
- NCT02365701
- Testing
- Motilitone 30mg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Dong-A ST Co., Ltd.
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251914
- Testing
- Esomeprazole
- Where
- 215 sites in Argentina, Belgium and 15 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Heartburn, Dyspepsia
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
Investigate the role of tegaserod in modulating gastric sensitivity to mechanical distention of the stomach
- Trial name
- NCT00171457
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novartis
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Dyspepsia, Chronic Gastritis
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
To study the anti free radical \& inflammatory effect and safety of Rebamipide in patients suffering of dyspepsia due to chronic gastritis.
- Trial name
- NCT00996788
- Testing
- Rebamipide
- Where
- Indonesia
- Volunteers
- 55 people
- Sponsor
- PT Otsuka Indonesia
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251992
- Testing
- Esomeprazole
- Where
- 183 sites in Austria, Belgium and 11 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Stress, Dyspepsia
Clinical Study of De-Stress & Happy Gut Powder for Stress and Indigestion in Adults.
The current study focuses on clinical validation of efficacy of nutraceutical product in relieving stress and functional dyspepsia symptoms in adults for gut health.
- Conditions
- Stress, Dyspepsia, Indigestion
- Trial name
- NCT06568965
- Testing
- De-stress & happy gut powder-U001, De-Stress & Happy Gut powder-I001
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Herbolab India Pvt. Ltd.
Dyspepsia
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
- Trial name
- NCT00232037
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- Novartis
Functional Dyspepsia
Clinical Trial of DA-5212 in Patients with Functional Dyspepsia
This study is to evaluate efficacy and safety of DA-5212 in patients with functional dyspepsia
- Trial name
- NCT05842408
- Testing
- DA-5212, DA-5212-R
- Where
- South Korea
- Volunteers
- 384 people
- Sponsor
- Dong-A ST Co., Ltd.
Acute and Chronic Inflammation, Dyspepsia
Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients
The purpose of this study is to evaluate the safety of an association with one anti-inflammatory and one gastroprotective agent compared to the one anti-inflammatory and one gastroprotective agent in patients with acute or…
- Trial name
- NCT01670552
- Testing
- Nimesulide + Pantoprazole, Naproxen + Esomeprazole
- Where
- Brazil
- Volunteers
- 490 people
- Sponsor
- EMS
Dyspepsia
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.
- Trial name
- NCT00232089
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 1,296 people
- Sponsor
- Novartis
Dyspepsia
The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.
"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting.
- Trial name
- NCT00303264
- Testing
- dexloxiglumide, Nexium (esomeprazole)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Forest Laboratories
Functional Dyspepsia
DLBS2411 Treatment For Functional Dyspepsia
This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients…
- Trial name
- NCT05248802
- Testing
- DLBS2411
- Where
- 8 sites in Indonesia
- Volunteers
- 106 people
- Sponsor
- Dexa Medica Group
Gastroesophageal Reflux Disease With Dyspepsia Symptoms
Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms
To evaluate the efficacy of 4-week lansoprazole (Takepron) therapy for subjective symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms
- Trial name
- LEGEND (NCT01990339)
- Testing
- Lansoprazole
- Volunteers
- 14,965 people
- Sponsor
- Takeda